+70.7%
CIFR vs MRNA
+88.2%
-17.5%
-97.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -8.7% | -3.4% | -5.3% | -8.2% |
| 7D | +11.3% | -10.1% | +21.4% | +13.0% |
| 30D | +3.5% | +126.7% | -123.2% | -23.8% |
| 3M | -26.6% | +184.1% | -210.8% | -50.8% |
| 6M | +18.1% | +143.3% | -125.2% | -17.0% |
| YTD | +14.5% | +359.9% | -345.4% | -36.0% |
| 1Y | +83.3% | +454.2% | -370.9% | -5.5% |
| 3Y | +461.5% | +26.0% | +435.5% | +337.3% |
| 5Y | +29.3% | -70.3% | +99.6% | +20.4% |
| All | +70.7% | +88.2% | -17.5% | +51.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling